Sleep

Falling asleep, sleep depth and sleep quality. Ranked by evidence grade, then user score. Each grade is for the use named on the card, which may not be this goal.

• Sleep
• Recovery & injury
• Fat loss
• Cognition & mood
• Libido & sexual health
• Longevity
• Skin & hair
• Immune
• Muscle & strength

Evidence grade Any grade A only B or better C or better D or better US FDA Any status Approved for this useApproved for another use onlyNot approved WADA (sport) Any status Not prohibitedProhibited or likely prohibitedNot named / unclear

8 of 8 peptides shown

1. B

   1.Ibutamoren mesylate

   Moderate human evidence · for raising GH/IGF-1 and lean mass

   FDA Not approved WADA Prohibited (S2.2.4)
   User score 3.5
   Outcomes: Positive 18 of 29 (62%), Mixed 6 of 29 (21%), Negative 3 of 29 (10%), No effect 2 of 29 (7%), Unclear 1 of 29 (3%)
   Men 45–60: 1 · everyone: 29 reports · approximate

   Why it’s listed: 10 of 29 user reports mention sleep.

2. C

   2.Delta sleep-inducing peptide

   Preliminary human data · for sleep

   FDA Not approved WADA Not named
   User score 4.0
   Outcomes: Positive 9 of 12 (75%), Mixed 1 of 12 (8%), Negative 1 of 12 (8%), Unclear 1 of 12 (8%)
   Men 45–60: 0 · everyone: 12 reports · approximate

   Why it’s listed: graded use mentions it; substance class mentions it; summary mentions it; 10 of 12 user reports mention sleep.

3. C

   3.Ipamorelin

   Preliminary human data · for raising growth hormone for sleep and body composition

   FDA Not approved WADA Prohibited (S2.2.4)
   User score 4.0
   Outcomes: Positive 34 of 48 (71%), Mixed 8 of 48 (17%), Negative 4 of 48 (8%), No effect 2 of 48 (4%)
   Men 45–60: 2 · everyone: 48 reports · approximate

   Why it’s listed: graded use mentions it; page tags mentions it; 22 of 48 user reports mention sleep.

4. C

   4.CJC-1295

   Preliminary human data · for raising growth hormone for body composition, recovery and sleep

   FDA Not approved WADA Prohibited (S2.2.4)
   User score 2.5
   Outcomes: Positive 6 of 12 (50%), Mixed 1 of 12 (8%), Negative 2 of 12 (17%), Unclear 3 of 12 (25%)
   Men 45–60: 1 · everyone: 12 reports · approximate

   Why it’s listed: graded use mentions it; page tags mentions it; 3 of 12 user reports mention sleep.

5. C

   5.Pinealon

   Preliminary human data · for cognition, sleep and neuroprotection

   FDA Not approved WADA Likely prohibited (S0)
   User score 2.5
   Outcomes: Positive 4 of 10 (40%), Mixed 1 of 10 (10%), Negative 4 of 10 (40%), No effect 1 of 10 (10%), Unclear 1 of 10 (10%)
   Men 45–60: 0 · everyone: 10 reports · approximate

   Why it’s listed: graded use mentions it; 5 of 10 user reports mention sleep.

6. C

   6.Sermorelin

   Preliminary human data · for adult growth-hormone 'optimisation', sleep and body composition

   FDA Approval withdrawn WADA Prohibited (S2.2.4)
   User score 2.0
   Outcomes: Positive 16 of 48 (33%), Mixed 10 of 48 (21%), Negative 16 of 48 (33%), No effect 3 of 48 (6%), Unclear 3 of 48 (6%)
   Men 45–60: 1 · everyone: 48 reports · approximate

   Why it’s listed: graded use mentions it; 13 of 48 user reports mention sleep.

7. C

   7.Epitalon

   Preliminary human data · for longevity, telomeres and sleep

   FDA Not approved WADA Likely prohibited (S0)
   User scoretoo few reports (8)
   Men 45–60: 0 · everyone: 8 reports · approximate

   Why it’s listed: graded use mentions it; 2 of 8 user reports mention sleep.

8. D

   8.Humanin

   Preclinical only · for longevity, metabolic and neuroprotective use

   FDA Not approved WADA Likely prohibited (S0)
   User scoretoo few reports (7)
   Men 45–60: 0 · everyone: 7 reports · approximate

   Why it’s listed: 2 of 7 user reports mention sleep.

User reports are anecdata, not evidence: self-selected, unverified, often combined with other compounds.